Abstract-The mouse is the most used animal for studying the genetic basis of cardiovascular diseases. However, the mechanisms of regulation of cardiovascular function in this animal are not yet well understood. The goal of this study was to evaluate the baroreflex, the Bezold-Jarisch cardiopulmonary reflex (BJR), and the chemoreflex in mice with hypertension induced by inhibition of NO using N-nitro-L-arginine-methyl ester (L-NAME). Basal mean arterial pressure (MAP) measured under anesthesia (urethane, 1 mg/g IP) was significantly higher in L-NAME (400 g/g IP for 7 days)-treated (HT) mice (nϭ7) compared with vehicle-treated (NT; nϭ10) animals (126Ϯ9 versus 79Ϯ2 mm Hg) without differences in heart rate (HR). Baroreflex sensitivity, evaluated using phenylephrine (1 g/g IV) was enhanced in HT mice compared with NT mice (Ϫ9.8Ϯ1.4 versus Ϫ4.9Ϯ0.5 bpm/mm Hg). The BJR, induced by phenylbiguanide (40 ng/g IV), was significantly attenuated in HT animals (MAP, Ϫ13Ϯ5%; HR, Ϫ39Ϯ6%) compared with NT animals (MAP, Ϫ38Ϯ5%; HR, Ϫ66Ϯ2%). The chemoreflex, induced by potassium cyanide (0.26 g/g IV), was significantly attenuated in HT animals (MAP, ϩ14Ϯ4%; HR, Ϫ8Ϯ2%) compared with NT animals (MAP, ϩ29Ϯ4%; HR, Ϫ15Ϯ4%). As has been observed in rats, chronic inhibition of NO synthase in mice results in arterial hypertension. Enhancement of baroreflex sensitivity and attenuation of BJR and chemoreflex seem to be mainly caused by inhibition of NO synthesis because individual analyses did not show positive correlation between changes in these reflexes and MAP levels in the HT group. Key Words: hypertension, experimental Ⅲ mice Ⅲ L-NAME Ⅲ baroreflex Ⅲ reflex M olecular biology techniques have permitted the development of genetically altered animals, in which genes controlling a specific function are overexpressed or disrupted to enable study of the contribution of the respective gene product to a specific disease. For practical reasons, the mouse has been the most genetically altered animal. Although transgenic mice are increasingly available to be used in cardiovascular research, knowledge about the normal physiological and pathophysiological characteristics of the murine cardiovascular system is still limited.
M olecular biology techniques have permitted the development of genetically altered animals, in which genes controlling a specific function are overexpressed or disrupted to enable study of the contribution of the respective gene product to a specific disease. For practical reasons, the mouse has been the most genetically altered animal. Although transgenic mice are increasingly available to be used in cardiovascular research, knowledge about the normal physiological and pathophysiological characteristics of the murine cardiovascular system is still limited.
After the first demonstration that chronic administration of the NO synthase inhibitor N-nitro-L-arginine methyl ester (L-NAME) causes arterial hypertension in rats 1 and our demonstration that the sympathetic nervous system plays a major role in L-NAME-induced hypertension in rats, 2 many interesting data have been obtained in this model of experimental hypertension. It has also been shown that L-NAME hypertension in rats is characterized by changes in baroreflex control of cardiovascular function [3] [4] [5] and a profound enhancement of the Bezold-Jarisch cardiopulmonary reflex. 6 Although it has been demonstrated that chronic administration of L-NAME also leads to arterial hypertension in mice, 7 no previous studies have systematically evaluated the effects of chronic inhibition of NO synthase on the neural reflex control of cardiovascular function in mice. Therefore, the purpose of this study was to evaluate the effects of chronic administration of L-NAME on arterial baroreflex, Bezold-Jarisch cardiopulmonary reflex, and chemoreflex in mice.
Methods

Animals
Experiments were conducted with male adult Swiss Webster mice (Physiological Sciences Animal Care) weighing 28 to 34 g. The animals were caged individually and had free access to food and water. Room temperature was maintained at 23Ϯ1°C, and a 12-hour/ 12-hour light/dark cycle was in effect. Experiments were conducted in accordance with the guidelines for the care and use of animals (Federation of Societies of Experimental Biology [FeSEB] ) and approved by the local committee.
Technique
The animals were treated with L-NAME (400 g/g IP daily, Sigma Chemical Co) or given vehicle (saline, 13 L/g IP daily) for 7 days. At the end of treatment, the animals were anesthetized with urethane (1 mg/g IP), which is known to maintain a great portion of the cardiovascular reflexes, 5 and supplemental anesthesia was administered as needed. Because mice are susceptible to hypothermia, especially when anesthetized, they were placed on a warming pad (averaging 38°C) throughout the surgical procedure and experimental protocols. Sterile heparinized saline-filled (50 U/mL) catheters (Microrenathane; Braintree Science Inc), 0.1 cm ODϫ0.06 cm ID, drawn over heat were inserted with aid of a dissecting microscopy (Opto Eletronica SA) into the carotid artery and femoral vein. The arterial catheter was used for direct measurement of pulsatile and mean arterial pressure (MAP) and heart rate (HR) (by a cardiotachometer) by a polygraph (Gould), and the venous catheter was used for administration of drugs. To avoid or minimize a possible influence of each drug on the subsequent test and based on our preliminary observation, a recovery period of Ϸ15 minutes was allowed for arterial pressure and HR to return to baseline values before administering the next drug.
Arterial baroreflex control of HR was determined in anesthetized mice by producing acute changes in arterial pressure with infusion (10 L IV for 10 seconds) of phenylephrine (1 g/g, Sigma) and sodium nitroprusside (1 g/g, Sigma) using an infusion pump (Harvard Apparatus Inc). To assess the Bezold-Jarisch reflex, a bolus injection of the 5-HT 3 -receptor agonist phenylbiguanide (40 ng/g IV, Sigma) was administered, and the simultaneous short-lasting fall of arterial pressure and bradycardia were recorded. The chemoreflex was evaluated by measuring the increase in arterial pressure and the nonreflex bradycardia following a bolus injection of potassium cyanide (0.26 g/g IV, Sigma).
At the end of experiments, the hearts were removed, and wet heart weight was used for evaluation of cardiac hypertrophy by measuring the ratio of heart weight to body weight.
Data Analysis
Results are reported as meanϮSEM. A 2-way ANOVA for repeated measurements was used for multiple comparisons, and the Student's t test was used for comparison of 2 independent samples. The level of significance was taken as PϽ0.05.
Results
As expected and observed in Figure 1 , mice treated with L-NAME for 7 days showed an expected arterial hypertension (126Ϯ7 mm Hg, PϽ0.01) compared with that of control mice (79Ϯ2 mm Hg), without significant differences in basal HR (703Ϯ15 versus 676Ϯ21 bpm, respectively). Figure 1 (bottom panels) shows that L-NAME caused an immediate and significant reduction of body weight, which was maintained throughout the treatment. No significant differences in heart weight-to-body weight ratio were observed between L-NAME and control groups. Figure 2 illustrates the reflex chronotropic responses to a phenylephrine-induced increase in arterial pressure of an L-NAME-treated mouse compared with a control mouse. As summarized in Figure 3 (left panels), although the phenylephrine-induced pressor responses were significantly attenuated in L-NAME-treated mice (ϩ33Ϯ6%, PϽ0.01, nϭ7) compared with control mice (ϩ97Ϯ5%, nϭ10), the reflex bradycardia was similar in both groups (Ϫ51Ϯ8% versus Ϫ56Ϯ6%), resulting in an increased baroreflex sensitivity in L-NAME-treated mice (Ϫ9.8Ϯ1.4 bpm/mm Hg, PϽ0.01) compared with control mice (Ϫ4.9Ϯ0.5 bpm/mm Hg, PϽ0.01). As shown in Figure 3 (right panels), the nitroprusside-induced hypotension was increased in L-NAME-treated mice compared with control mice, but no reflex tachycardia was observed in both groups, probably because of the high resting HR values.
Top panels of Figure 4 show typical recordings of phenylbiguanide-induced hypotension and bradycardia, which characterizes the Bezold-Jarisch reflex, demonstrating a smaller response in both duration and magnitude in the L-NAME-treated mice compared with the control mice. Figure 4 (bottom panels) summarizes the values of the Bezold-Jarisch reflex testing, showing a significant reduction Figure 1 . Top panels, Basal arterial pressure and HR in anesthetized mice treated with L-NAME (nϭ7) or vehicle (control; nϭ10) for 7 days. Bottom panels, Changes in body weight during the treatment, and wet heart weight-or heart weight-to-body weight ratio at the end of the treatment. Values are meanϮSEM. *PϽ0.05 and **PϽ0.01 vs control group.
of the hypotension and bradycardia in L-NAME-treated mice (Ϫ14Ϯ5 mm Hg and Ϫ274Ϯ44 bpm, PϽ0.01, nϭ7) compared with control mice (Ϫ31Ϯ5 mm Hg and Ϫ461Ϯ26 bpm, nϭ10).
The chemoreflex test showed significantly decreased pressor and chronotropic responses in L-NAME-treated mice (MAP, ϩ14Ϯ4%; HR, Ϫ8Ϯ2%; nϭ6) compared with vehicle-treated mice (MAP, ϩ29Ϯ4%; HR, Ϫ15Ϯ4%; nϭ7).
Discussion
Studies into mechanisms underlying physiology and pathophysiological states have increasingly employed transgenic mouse models, in which targeted genes are functionally altered or deleted using molecular biology thechnology. 8 -11 Concomitant to this process and despite its small size, the mouse is becoming an important species in cardiovascular research and could help us elucidate mechanisms of arterial hypertension. In this respect, recent studies have described the successful development of mineralocorticoid deoxycorticosterone-salt, 12 renovascular, 12 and L-NAME 7 hypertension in mice. Presently, there is a lack of knowledge about the cardiovascular control in mice. This is the first study to systematically evaluate the neural reflex control of cardiovascular function in nontransgenic murine models of hypertension.
In our opinion, the use of urethane as an anesthetic agent was a satisfactory choice because it enabled us to differentiate the effects of L-NAME on arterial blood pressure and on neural reflexes of cardiovascular control compared with those of vehicle-treated mice without conflicting with the standards of the local animal care and use committee. Although mice are quite active, further studies are required to evaluate the mechanisms of cardiovascular control in conscious animals and in other murine models of experimental hypertension.
The present results are in good agreement with other reports showing that chronic administration of L-NAME causes arterial hypertension in mice 7, 13 and rats 1 without significant changes in HR and heart weight. To achieve a high blood pressure value and a possible cardiac hypertrophy in the treated animals, we used a nontoxic high dose of L-NAME 13 because the arterial pressure levels are dependent on the dose of L-NAME. 7, 13 Although the heart weight-tobody weight ratio (Figure 1 , bottom panels) could indicate a tendency to cardiac hypertrophy in L-NAME-treated mice, this cannot be considered because there were no significant differences in heart weight between the 2 groups and because L-NAME-treated mice showed a reduced body weight throughout the treatment. The decrease in body weight in this group may be mainly caused by L-NAME treatment because NO seems to be involved in the regulation of appetite in mice. 14 During the baroreflex testing and consistent with observations in rats, [3] [4] [5] L-NAME-treated mice showed an attenuated pressor response to phenylephrine because, at least in part, the basal values of arterial pressure were already elevated. In contrast, it is conceivable that the exaggerated nitroprussideinduced hypotension in L-NAME mice could be caused by both the high basal arterial pressure levels and the direct donation of NO to the vessels. This observation indicates that the vascular relaxing components are functionally preserved. We found an enhanced sensitivity of the baroreflex against acute increases in arterial pressure, which could indicate that this neural reflex is upregulated in L-NAME-treated mice the same as has been observed in rats presenting L-NAME hypertension and high cardiac sympathetic tonus. 3 We speculate that the lack of reflex tachycardia during nitroprussideinduced falls in arterial pressure in both L-NAME-treated and vehicle-treated mice could be because of a high cardiac sympathetic tonus as indicated by the high basal HR values in both groups. This hypothesis is based on another report 15 showing that HR in Swiss mouse is predominantly under sympathetic control and that atropine has minor effects on cardiac rate. The most used method to evaluate the baroreflex sensitivity in other species has been through several randomly assigned doses of phenylephrine and sodium nitroprusside. However, considering the small size of the mouse and trying to avoid volume overloading, we opted for an infusion method that has been used in other studies with human beings 16 and rats 17 that required short-term tests. The development of more suitable approaches will be helpful to evaluate in a better manner the baroreflex function in the mouse.
Because it is well known that the cardiopulmonary reflexes contribute to the cardiovascular control by providing neurohumoral drive to the cardiovascular system and by interacting with arterial baroreflex, 18 -20 the Bezold-Jarisch reflex was also evaluated in this model of hypertension. We observed that both the magnitude and duration of the phenylbiguanide- induced response was decreased in L-NAME-treated mice, but our data do not allow us to speculate in which part of the neural reflex arch it is located. Consistent with the observations of an enhanced baroreflex in L-NAME hypertensive mice, it is not entirely surprising that we have found in this study an attenuation of the Bezold-Jarisch reflex, perhaps as an inhibitory compensation. This result is opposite to our previous observations in L-NAME hypertensive rats that showed that this cardiopulmonary reflex was profoundly enhanced. 6 Our data do not allow us to speculate if this discrepancy between species is due to different hemodynamic responses to NO synthase blockade. However, these differences could not be attributed to a high sympathetic drive to the heart 15 and consequently to a high HR alone because the reflex bradycardia to phenylephrine during the baroreflex testing was enhanced in L-NAME-treated mice. Both the enhanced baroreflex and the attenuated Bezold-Jarisch reflex do not appear to be secondary to arterial hypertension because individual analyses did not show positive correlations between changes in these reflexes and arterial blood pressure levels in L-NAME-treated mice. Thus, this could be mainly caused by inhibition of NO synthesis.
The chemoreflex was also significantly attenuated in L-NAME-treated mice. This finding corroborates the hypothesis that an enhanced buffering function of the arterial baroreflex in this hypertension model leads to a hyporesponsiveness of the cardiopulmonary reflexes and chemoreflex. 18 -20 In summary, we report that the chronic hypertensive effect of L-NAME is accompanied by an augmented sensitivity of the arterial baroreceptor control of HR to acute increases of arterial pressure and a significant attenuation of the Bezold-Jarisch reflex and the chemoreflex in mice. Although we can rule out the possibility of these changes be related with the arterial hypertension, the mechanisms by which the inhibition of the NO synthase mediates this changes remain unknown. 
